Free Trial
NASDAQ:GOVXW

GeoVax Labs (GOVXW) Stock Price, News & Analysis

GeoVax Labs logo
$0.10 0.00 (-1.96%)
(As of 12/26/2024 05:22 PM ET)

About GeoVax Labs Stock (NASDAQ:GOVXW)

Key Stats

Today's Range
$0.10
$0.10
50-Day Range
$0.10
$0.15
52-Week Range
$0.02
$0.65
Volume
101 shs
Average Volume
21,155 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Receive GOVXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

GOVXW Stock News Headlines

GeoVax adjourns Special Meeting due to low quorum
GOVXW GeoVax Labs, Inc. WT EXP 092925
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
Noble Financial Keeps Their Buy Rating on GeoVax Labs (GOVX)
See More Headlines

GOVXW Stock Analysis - Frequently Asked Questions

GeoVax Labs' stock was trading at $0.03 at the start of the year. Since then, GOVXW shares have increased by 233.3% and is now trading at $0.10.
View the best growth stocks for 2024 here
.

Shares of GOVXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GOVXW
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.09 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:GOVXW) was last updated on 12/27/2024 by MarketBeat.com Staff
From Our Partners